skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Your recent comments on DOO:
We think DOO is still good. Solid earnings growth is still expected, and at only 12X earnings investors are not expecting much. As rates rose investors shied away from the stock, but as rates peak (as long as jobs remain strong) we would expect confidence to return here. It has beaten estimates 8 quarters in a row and the last quarter's EPS beat by 6%.

My question:
Your comments don't suggest that the company has done anything wrong (quite the opposite really) and yet the stock has gone down by 50%. Unlike KXS, NFI, SIS, TSGI and others that had announcements that drove significant temporary declines, I can't see anything like that here. Is this stock therefore not being punished unfairly and ripe for rebound? To what do you attribute the wholesale abandonment of the stock? It would not seem that such strong selling pressure is warranted. What is the case against buying vs FOR buying?
Read Answer Asked by Tim on February 21, 2019
Q: Is not 2019 projections significantly better then 2018? A company want to be responsible they are penalized???

“As the timing of the full impact of these cost saving programs is difficult to determine, we believe it prudent to re-evaluate our guidance for 2019. Consequently, for 2019 we are now forecasting revenue of $385 to $400 million and adjusted EBITDA in a range of $55 to $60 million, excluding any contributions from potential future acquisitions.”
Read Answer Asked by fwb181 on February 20, 2019
Q: Is there a "reason " behind SIS announcing its preliminary and un audited year end and last quarter financial results suddenly , which it had never done in the past ? The figures were not that bad when compared to street estmates, though EBITDA was marginally lower . Is something "brewing " for SIS which an ordinary investor is unaware?
Read Answer Asked by Sriram on February 20, 2019
Q: What are your thoughts on SIS's premature earnings release with disappointing EBITDA miss and lowered guidance? Also they pointed to less acquisitions and more focusing on getting the house in order. Obviously not good to hear they are struggling in Europe. I have always liked this mgmt and I feel they handled this primarily negative release well and I appreciate their transparency and guidance on how they plan to fix the issues. But what does this mean for a company that has struggled for the last 5 months, are we now looking at another year plus of lowered guidance, less or no acquisitions, restructuring, and beaten down share price? Thanks
Read Answer Asked by Adam on February 20, 2019
Q: Simple question

Does 5i view this deal as significant in any way (from the Globe)

Knight Therapeutics Inc. (GUD-T) announced the closing of a strategic financing agreement in Moksha8 Inc., a specialty pharmaceutical company focused on licensing and marketing “innovative and established therapeutics” in Latin America, for up to US$125-million.

Under the agreement, Knight will initially lend Moksha8 up to US$25-million in working capital funding, of which US$10-million will be issued at closing. Knight said it may issue up to an additional US$100-million in funding for M&A and the acquisition of new licenses.
Read Answer Asked by Tim on February 19, 2019
Q: Hi,
could I get your take on the latest quarterly release please for AEM? There were a lot of charges/impairment loses which I find complicates things when trying to determine how the company business is doing.
Fundamentally, was this is positive quarter? Also, what caused such a large impairment loss? I see they reduced the goodwill on 3 mines. Does this mean they paid to much for these in the past?
Thanks,
Dan
Read Answer Asked by Daniel on February 19, 2019
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!